Study of TVAX-028 for chronic hepatitis B
Part of Infections clinical trials.
This trial tests an investigational drug called TVAX-028 for people with chronic hepatitis B. The study aims to see if it is safe and how the body handles it. It may be an option if you are already on a stable antiviral treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with chronic hepatitis B.
- You are currently on a stable antiviral medication for hepatitis B.
- You have a negative hepatitis B e-antigen (HBeAg) test.
- You have no other serious liver diseases or conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental injection called TVAX-008 for people with chronic hepatitis B who are already on antiviral therapy. It aims to see if it can help control the virus and potentially lead to a functional cure.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests an experimental vaccine therapy to help control or possibly cure chronic hepatitis B. It is designed to see whether the treatment is safe and how well it affects the hepatitis B virus in adults.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
Hear when a new HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.